FACULTY
Anat Galor, MD, MSPH
Professor of Ophthalmology
Bascom Palmer Eye Institute
Miller School of Medicine
University of Miami
Miami, FL
Jacob Sands, MD
Assistant Professor and Associate Chair of Thoracic Oncology
Dana-Farber Cancer Institute
Boston, MA
Càrlo Pelino, OD, FAAO
Associate Professor
Pennsylvania College of Optometry
Drexel University
Chief at the Eye Institute at Chestnut Hill
Philadelphia, PA
PROGRAM OVERVIEW
This multidisciplinary Clinical Minutes program brings together specialists from the oncology and ophthalmic communities to learn from each other about ocular toxicities associated with certain TROP-2-directed antibody-drug conjugates (ADCs). Their in-depth discussion includes the mechanisms of action of TROP-2-directed ADCs and how they may contribute to ocular toxicities, as well as the nature of ocular toxicities associated with these agents, including their frequency and severity. The panelists cover when to refer patients to an eye care provider, the role of the eye care provider, and best practices for prevention and management of ocular events. The program also includes a patient vignette that helps understand the patient experience and illustrate the points discussed by the panel.
TARGET AUDIENCE
This activity aims to increase oncologist, pulmonologist, breast cancer specialist, ophthalmologist and optometrist awareness and knowledge of prophylactic management, identification and treatment strategies for ocular adverse events associated with TROP2-directed antibody-drug conjugates, thereby supporting appropriate future integration into clinical practice for improved patient outcomes.
LEARNING OBJECTIVES
Upon completion of this activity, attendees will have improved ability to:
- Summarize the ocular side effects associated with TROP2-directed antibody-drug conjugate (ADC) use in non-small cell lung cancer (NSCLC) and breast cancer
- Identify the prophylaxis, assessments, and treatment algorithm for ocular side effects caused by TROP2 ADCs, including considerations for ADC dose modification
- Explain the oncologist and ophthalmologist or optometrist roles in managing ocular side effects caused by ADC in patients with NSCLC or breast cancer
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in this enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of up to 1.0 ANCC contact hours.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty Member | Disclosures |
| Anat Galor, MD, MSPH | Has nothing to disclose |
| Jacob Sands, MD | Receives consulting fees from AbbVie, Amgen, AstraZeneca, Daiichi, Boehringer Ingelheim, Fosun, Pharma Mar, Jazz Pharmaceuticals, Merck, Medtronic, Lilly, Sanofi, and Gilead |
| Càrlo Pelino, OD, FAAO | Has nothing to disclose |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, CEO of Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, Sr VP of Operations for Med Learning Group, has nothing to disclose.
- Kim L. Farina, PhD, Medical Director for Med Learning Group, has nothing to disclose.
- Tom Bregartner, MBA, VP of Outcomes and Accreditation for Med Learning Group, has nothing to disclose.
- Aimee Meissner, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
- A medical reviewer from CME Peer Review LLC, has nothing to disclose.
- Naomi De Brito, Program Manager for Med Learning Group, has nothing to disclose.
- Arpan Patel, MD, has nothing to disclose.
- M. Susan Burke, MD, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc). Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: July 17, 2025
EXPIRATION DATE: July 17, 2026
Copyright © 2025 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
